Jianyu Rao, MD, FCAP


Professor of Pathology and Epidemiology
Chief of Cytopathology
Medical Director, UCLA Cytotechnology School
Director, International Telepathology Program
Department of Pathology & Laboratory Medicine
UCLA Ronald Reagan Medical Center
10833 Le Conte Avenue
Los Angeles, CA 90095, USA

Biography

Dr. Rao is a Diagnostic Surgical/Cytopathologist and established investigator in cancer biomarker studies. Prior to be a Pathologist, he was already an established molecular epidemiologist involved in multiple high profile cancer prevention studies. He completed his Anatomic/Clinical pathology residency and Cytopathology Fellowship at UCLA, and joined the UCLA Department of Pathology as a Faculty in 1999. Dr. Rao is a Full Professor and the Chief of Cytopathology, Ex-director of Gynecological Pathology, the Director of International Telepathology, and the Medical Director of Cytotechnology School. He has dual appointments in Pathology and Epidemiology. He is also a recipient of Thousand-Talent program of China. He is particularly well known for cancer biomarker studies, as he has over 30 year experience in this area. He has been invited to be a Speaker for over 100 meetings and occasions locally, nationally and internationally for topics including urine cytology, Fine Needle Aspiration cytology, gynecological pathology, and cancer molecular biomarkers. Dr. Rao has an active role in teaching and research, with continuous funding from NIH or other agencies for cancer biomarker and prevention studies in the last 25 years, with over 140 peer-reviewed research publications.

Research Interest

His research interests include: Developing new technologies for pathology especially cytopathology, including imaging analysis, nanotechnology and telepathology.

Scientific Activities

HONORS AND SPECIAL AWARDS (SELECTED)

• Provosts Research Fellowship Award, University of Oklahoma Health Sciences Center, (1987-1989)
• Young Investigator Award of Seventh Annual Meeting of Clinical Applications of Cytometry, (1992)
• Richard F. Dwyer and Elaine W. Dwyer Award for Excellence from the Jonsson Comprehensive Cancer Foundation, (1996)
• Finalist for ASCP/CAP Pathology Resident Award Competition, Spring Meeting, (1998)
• First award, LASOP Pathology Research Competition, (1999)
• USCAP Annual Meeting received Stowell – Orbison Certificate of Merit award for resident research project entitled Prostate Stem Cell Antigen as an Adjunctive Marker for Urothelial Carcinoma in Urine Cytology Specimens (2007)
• Nominee, Geno Saccomanno, M.D. New Frontiers in Cytology Award, (2009)
• Nominee, Shaw Prize in Life Science and Medicine, (2010)
• Guangji Scholar, Zhejiang University Second Affiliate Hospital, China, (2011)
• Thousand-Talent Program, Central Organization Department, China, (2013)
• Visiting Professor, Zhejiang University, (2013)
• Huaxia Education Award, Huaxia Pathology Association (ipathology.cn), (2013)

Publications

RESEARCH PAPERS

1. Qiao YL, Taylor PR, Yao SX, et al. Relation of radon exposure and tobacco use to lung cancer among tin miners in Yunnan Province, China. Am J Ind Med. 1989; 16(5): 511-521.
2. Taylor PR, Qiao YL, Schatzkin A, et al. Relation of arsenic exposure to lung cancer among tin miners in Yunnan Province, China. Br J Ind Med. 1989; 46(12): 881-886.
3. Lubin JH, Qiao YL, Taylor PR, et al. Quantitative evaluation of the radon and lung cancer association in a case control study of Chinese tin miners. Cancer Res. 1990; 50(1): 174-180.
4. Jones PL, OHare CM, Bass RA, Rao JY, Hemstreet GP, Hurst RE. Quantitative immunofluorescence, anti-ras p21 antibody specificity, and cellular oncoprotein levels. Biochem Biophys Res Commun. 1990; 167(2): 464-470. doi: 10.1016/0006-291X(90)92046-3
5. Rao JY, Hurst RE, Bales WD, et al. Cellular F-actin levels as a marker for cellular transformation: relationship to cell division and differentiation. Cancer Res. 1990; 50(8): 2215-2220.
6. Hemstreet GP 3rd, Hurst RE, Bass RA, Rao JY. Quantitative fluorescence image analysis in bladder cancer screening. J Occup Med. 1990; 32(9): 822-828.
7. Hurst RE, Jones PL, Rao JY, Hemstreet GP 3rd. Molecular and cellular biological approaches and techniques in the detection of bladder cancer and enhanced risk for bladder cancer in high-risk groups. J Occup Med. 1990; 32(9): 854-862.
8. Rao JY, Hemstreet GP 3rd, Hurst RE, Bonner RB, Min KW, Jones PL. Cellular F-actin levels as a marker for cellular transformation: correlation with bladder cancer risk. Cancer Res. 1991; 51(11): 2762-2767.
9. Hemstreet GP 3rd, Rollins S, Jones P, et al. Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J Urol. 1991; 146(6): 1525-1529.
10. Hemstreet GP 3rd, Rao JY, Hurst RE, et al. Intermediate endpoint biomarkers for chemoprevention. J Cell Biochem Suppl. 1992; 16I: 93-110. doi: 10.1002/jcb.240501320
11. Bi W, Rao JY, Hemstreet GP, et al. Field molecular epidemiology. Feasibility of monitoring for the malignant bladder cell phenotype in a benzidine-exposed occupational cohort. J Occup Med. 1993; 35(1): 20-27.
12. Rao JY, Hemstreet GP 3rd, Hurst RE, et al. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA. 1993; 90(17): 8287-8291.
13. Bonner RB, Hemstreet GP 3rd, Fradet Y, Rao JY, Min KW, Hurst RE. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer. 1993; 72(8): 2461-2469.
14. Hemstreet GP, Rao JY. Study looks at alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. A.U.A. Today. 1995; 8(10): 1.
15. Bane BL, Rao JY, Hemstreet GP. Pathology and staging of bladder cancer. Semin Oncol. 1996; 23(5): 546-570.
16. Rao JY, Bonner RB, Hurst RE, Liang YY, Reznikoff CA, Hemstreet GP 3rd. Quantitative changes in cytoskeletal and nuclear actins during cellular transformation. Int J Cancer. 1997; 70(4): 423-429. doi: 10.1002/(SICI)1097-0215(19970207)70:4<423::AID-IJC9>3.0.CO;2-Y
17. Hu N, Taylor PR, Rao JY, et al. Quantitative fluorescence image analysis of DNA content and nuclear morphology on esophageal balloon cytology smears and subsequent development of esophageal and gastric cardia cancer in Linxian, China. Cancer Epidemiol Biomarkers Prev. 1998; 7(1): 59-64.
18. Rao JY, Apple SK, Hemstreet GP, Jin Y, Nieberg RK. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev. 1998; 7(11): 1027-1033.
19. Hemstreet GP 3rd, Rao J, Hurst RE, Bonner RB, Mellott JE, Rooker GM. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prev. 1999; 23(2): 163-171.
20. Rao JY, Jin YS, Zheng Q, Cheng J, Tai J, Hemstreet GP 3rd. Alterations of the actin polymerization status as an apoptotic morphological effector in HL-60 cells. J Cell Biochem. 1999; 75(4): 686-697. doi: 10.1002/(SICI)1097-4644(19991215)75:4<686::AID-JCB14>3.0.CO;2-F
21. Rao JY, Apple SK, Jin Y, Lin S, Nieberg RK, Hirtschowitz SL. Comparative polymerase chain reaction analysis of c-myc amplification on archival breast fine-needle aspiration materials. Cancer Epidemiol Biomarkers Prev. 2000; 9(2): 175-179.
22. Cohan P, Hirschowitz S, Rao JY, Tanavoli S, Van Herle AJ. Amyloid goiter in a case of systemic amyloidosis secondary to ankylosing spondylitis. J Endocrinol Invest. 2000; 23(11): 762-764.
23. Hemstreet GP 3rd, Yin S, Ma Z, et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst. 2001; 93(6): 427-436. doi: 10.1093/jnci/93.6.427
24. Lin S, Hirschowitz SL, Williams C, Shintako P, Said J, Rao JY. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides. Cancer Detect Prev. 2001; 25(2): 202-209.
25. Rao JY. Targeting actin remodeling profiles for the detection and management of urothelial cancers–a perspective for bladder cancer research. Front Biosci. 2002; 7: e1-e8.
26. Rao JY, Seligson D, Hemstreet GP. Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides. Biotechniques. 2002; 32(4): 924-926.
27. Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao JY, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene. 2002; 21(41): 6289-6298. doi: 10.1038/sj.onc.1205785
28. Rao JY, Seligson D, Visapaa H, et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002; 95(6): 1247-1257. doi: 10.1002/cncr.10823
29. Han KR, Pantuck AJ, Belldegrun AS, Rao JY. Tumor markers for the early detection of bladder cancer. Front Biosci. 2002; 7: e19-e26.
30. Visapää H, Seligson D, Huang Y, et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003; 30(6): 387-389.
31. Visapää H, Seligson D, Eeva M, et al. 8q24 amplification in transitional cell carcinoma of bladder. Appl Immunohistochem Mol Morphol. 2003; 11(1): 33-36.
32. Espineda C, Seligson DB, James Ball W Jr, et al. Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer. 2003; 97(8): 1859-1868. doi: 10.1002/cncr.11267
33. Visapää H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003; 61(4): 845-850.
34. Cheng L, Reiter RE, Jin Y, et al. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol. 2003; 169(6): 2094-2100.
35. Zhang W, Wang L, Chang A, Jin Y, Rao JY. Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China. Cancer Detect Prev. 2003; 27(4): 243-239.
36. Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF. Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev. 2003; 27(5): 397-404.
37. Mao GE, Reuter VE, Cordon-Cardo C, et al. Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development. Cancer Epidemiol Biomarkers Prev. 2004; 13(3): 383-390.
38. Zhang L, Maul RS, Rao JY, et al. Expression pattern of the novel gene EG-1 in cancer. Clin Cancer Res. 2004; 10(10): 3504-3508. doi: 10.1158/1078-0432.CCR-03-0467
39. Rao JY, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets. 2004; 4(4): 345-354.
40. Zhang Q, Zhang ZF, Rao JY, et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer. 2004; 111(6): 849-857. doi: 10.1002/ijc.20334
41. Sartippour MR, Rao JY, Apple S, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer. 2004; 49(1): 59-65.
42. Lu QY, Jin YS, Zhang Q, et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Lett. 2004; 216(1): 9-20.
43. Sartippour MR, Seeram NP, Heber D, et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol. 2005; 26(1): 121-127.
44. Lu QY, Jin YS, Pantuck A, et al. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res. 2005; 11(4): 1675-1683. doi: 10.1158/1078-0432.CCR-04-1608
45. Wiriosuparto S, Krassilnik N, Bhuta S, Rao JY, Hirschowitz S. Solitary fibrous tumor: report of a case with an unusual presentation as a spindle cell parotid neoplasm. Acta Cytol. 2005; 49(3): 309-313.
46. Wiley DJ, Huh J, Rao JY, et al. Methylation of human papillomavirus genomes in cells of anal epithelia of HIV-infected men. J Acquir Immune Defic Syndr. 2005; 39(2): 143-151.
47. Lu M, Zhang L, Maul RS, et al. The novel gene EG-1 stimulates cellular proliferation. Cancer Res. 2005; 65(14): 6159-6166.
48. Chuang SC, Hashibe M, Yu GP, et al. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett. 2006; 238(1): 42-52.
49. Mu LN, Lu QY, Yu SZ, et al. Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer. 2005; 116(6): 972-983.
50. Cao W, Cai L, Rao JY, et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005; 104(11): 2400-2408.
51. Matei D, Emerson RE, Lai YC, et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006; 25(14): 2060-2069.
52. Wiley DJ, Wiesmeier E, Masongsong E, et al. Proof of Principle Study Investigative Group. Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev. 2006; 15(5): 915-920.
53. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006; 5(5): 1227-1238.
54. Li S, Wang H, Hu J, et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer. 2006; 118(12): 3078-3083. doi: 10.1002/ijc.21774
55. Jin Y, Iwata KK, Belldegrun A, et al. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006; 5(7): 1754-1763.
56. Zhang W, Yang YC, Zhang BN, et al. Biomarker analysis on breast ductal lavage cells in women with and without breast cancer. Int J Cancer. 2006; 119(2): 359-364. doi: 10.1002/ijc.21854
57. Zeng G, Aldridge ME, Tian X, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006; 177(6): 3582-3589.
58. Hung RJ, Zhang ZF, Rao JY, et al. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol. 2006; 176(3): 1192-1197.
59. Sartippour MR, Pietras R, Marquez-Garban DC, et al. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 2006; 27(12): 2424-2433.
60. Yang YC, Lu ML, Rao JY, Wallerand H, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006; 95(11): 1455-1458. doi: 10.1038/sj.bjc.6603456
61. Xiao GS, Jin YS, Lu QY, et al. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer. 2007; 120(1): 111-120. doi: 10.1002/ijc.22164
62. Sullivan P, Rao J, Cheng L, Cote RJ. Classical pathology versus molecular pathology in renal cell carcinoma. Curr Urol Rep. 2007; 8(1): 5-11.
63. Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW. Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol. 2007; 19(2): 171-176.
64. Lu QY, Jin YS, Zhang ZF, et al. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab Invest. 2007; 87(5): 456-465. doi: 10.1038/labinvest.3700534
65. Klatte T, Rao JY, Ribas A, Pantuck AJ. Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology. 2007; 69(5): 982.e7-9.
66. Shi R, Rao J, Xie Q, Gang X, Lun J, Cheng L. A Study of Prostataplex™ on Benign Prostatic Hyperplasia (BPH). Shanghai Journal of Preventive Medicine. 2007; 19: 49-52.
67. Liu W, Chang BL, Cramer S, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res. 2007; 13(17): 5028-5033.
68. Matei D, Kelich S, Cao L, et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology & Therapy. 2007; 6(12): 1951-1959. doi: 10.4161/cbt.6.12.4976
69. Cross SE, Jin YS, Rao J, Gimzewski JK. Nanomechanical analysis of cells from cancer patients. Nature Nanotechnol. 2007; 2(12): 780-783.
70. Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A, Rao J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J Urol. 2008; 179(2): 610-615.
71. Sartippour MR, Seeram NP, Rao JY, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008; 32(2): 475-480.
72. Norris AJ, Sartippour MR, Lu M, et al. Nitroxyl inhibits breast tumor growth and angiogenesis. Int J Cancer. 2008; 122(8): 1905-1910.
73. Chen H, Boontheung P, Loo RR, et al. Proteomic analysis to characterize differential mouse strain sensitivity to cadmium-induced forelimb teratogenesis. Birth Defects Res A Clin Mol Teratol. 2008; 82(4): 187-199.
74. Cross SE, Jin YS, Tondre J, Wong R, Rao J, Gimzewski JK. AFM-based analysis of human metastatic cancer cells. Nanotechnology. 2008; 19(38): 384003.
75. Xie Q, Shi R, Xu G, Cheng L, Shao L, Rao J. Effects of AR7 Joint Complex on arthralgia for patients with osteoarthritis: results of a three-month study in Shanghai, China. Nutr J. 2008; 7: 31. doi: 10.1186/1475-2891-7-31.
76. Park SL, Chang SC, Cai L, et al. Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev. 2008; 17(11): 3193-3202. doi: 10.1158/1055-9965.EPI-08-0523
77. Rettig MB, Heber D, An J, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008; 7(9): 2662-2671. doi: 10.1158/1535-7163.MCT-08-0136
78. Karam A, Berek JS, Stenson A, Rao J, Dorigo O. HER-2/neu targeting for recurrent vulvar Pagets disease A case report and literature review. Gynecol Oncol. 2008; 111(3): 568-571. doi: 10.1016/j.ygyno.2007.12.014
79. Lu QY, Yang Y, Jin YS, Zhang ZF, et al. Effects of green tea extract on lung cancer A549 cells: proteomic identification of proteins associated with cell migration. Proteomics. 2009; 9(3): 757-767. doi: 10.1002/pmic.200800019
80. Klatte T, Seligson DB, Rao JY et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009; 115(7): 1448-1458.
81. Klatte T, Said JW, de Martino M, et al. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol. 2009; 181(4): 1558-1564. doi: 10.1016/j.juro.2008.11.098
82. Sullivan PS, Nooraie F, Sanchez H, et al. Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a split-sample study. Cancer. 2009; 117(3): 167-173. doi: 10.1002/cncy.20026
83. Liu YH, Xu FP, Rao JY, et al. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer. Am J Clin Pathol. 2009; 132(1): 74-79.
84. Sheng JQ, Li SR, Wu ZT, Xia CH, Wu X, Chen J, Rao J. Transferrin dipstick as a potential novel test for colon cancer screening: a comparative study with immuno fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2182-2185.
85. Hussain SK, Mu LN, Cai L, et al. Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2304-2309. doi: 10.1158/1055-9965.EPI-09-0233.
86. Nosov V, Park S, Rao J, Memarzadeh S. Non-Peutz-Jeghers syndrome associated ovarian sex cord tumor with annular tubules: a case report. Fertil Steril. 2009; 92(4): 1497.e5-8. doi: 10.1016/j.fertnstert.2009.07.1002
87. King M, Poya H, Rao J, et al. CXCL13 expression in Chlamydia trachomatis infection of the female reproductive tract. Drugs Today (Barc). 2009; 45 (Suppl B): 125-34.
88. Li HX, Li M, Li CL, et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol. 2010; 32(1): 45-52.
89. Sheng JQ, Li SR, Su H, et al. Fecal cytology in conjunction with immunofecal occult blood test for colorectal cancer screening. Anal Quant Cytol Histol. 2010; 32(3): 131-135.
90. Klatte T, Seligson DB, Rao JY, et al. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 2010; 183(6): 2403-2408.
91. Park SL, Bastani D, Goldstein BY, et al.Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis. 2010 ; 31(7): 1264-1271.
92. Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res. 2010; 2(4): 412-440.
93. Jin P, Lu XJ, Sheng JQ, et al. Estrogen stimulates the expression of mismatch repair gene hMLH1 in colonic epithelial cells. Cancer Prev Res. 2010; 3(8): 910-916.
94. Mao JT, Nie WX, Tsu IH, et al. White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-{gamma} and 15-lipoxygenases. Cancer Prev Res (Phila). 2010; 3(9): 1132-1140.
95. Oh SS, Chang SC, Cai L, et al. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer. 2010; 127(9): 2169-2182.
96. Wilson L, Cross S, Gimzewski J, Rao J. Nanocytology: a novel class of biomarkers for cancer management. IDrugs. 2010; 13(12): 847-851.
97. Xie C, Kim HJ, Haw JG, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011; 9: 43. doi: 10.1186/1479-5876-9-43
98. Cross SE, Jin YS, Lu QY, Rao J, Gimzewski JK. Green tea extract selectively targets nanomechanics of live metastatic cancer cells. Nanotechnology. 2011; 22(21): 215101.
99. Izadyar F, Wong J, Maki C, et al. Identification and characterization of repopulating spermatogonial stem cells from the adult human testis. Hum Reprod. 2011; 26(6): 1296-1306. doi: 10.1093/humrep/der026
100. Mao JT, Roth MD, Fishbein MC, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res. 2011; 4(7): 984-993.
101. Li Y, Chang SC, Goldstein BY, et al. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol. 2011; 35(4): 362-368.
102. Liu F, Hsing AW, Wang X, et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci. 2011; 102(10): 1916-1920.
103. Rao J, Levin M, Zhao C. Premature conclusions on HPV-only testing. Lancet Oncol. 2011; 12(11): 992-993.
104. Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine. 2011.
105. Penner KR, Dorigo O, Aoyama C, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2011.
106. Zhang L, Pang E, Loo RR, et al. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells. Proteomics. 2011; 11(24): 4638-4647. doi: 10.1002/pmic.201100242
107. Gu G, Cheng W, Yao C, et al. Quantitative proteomics analysis by isobaric tags for relative and absolute quantitation identified Lumican as a potential marker for acute aortic dissection. J Biomed Biotechnol. 2011; 2011: 920763.
108. Vora AA, Lai CK, Rao JY, Apple SK, Moatamed NA. Paraganglioma with unusual presentation in parotid gland: A diagnostic dilemma in fine needle aspiration. Cytojournal. 2012; 9: 26.
109. Mao GE, Harris DM, Moro A, et al. A joint effect of new western diet and retinoid X receptor alpha prostate-specific knockout with development of high-grade prostatic intraepithelial neoplasia in mice-A preliminary study. Prostate. 2012; 72(10): 1052-1059.
110. Gossett D, Tse H, Lee S, et al. Hydrodynamic stretching of single cells for large population mechanical phenotyping. PNAS. 2012; 109(20): 7630-7635.
111. Lu QY, Jin Y, Mao JT, et al. Green Tea Inhibits Cycolooxygenase-2 in Non-Small Cell Lung Cancer Cells through the Induction of Annexin-1. Biochem Biophys Res Commun. 2012.
112. Xu J, Mo Z, Ye D, et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet. 2012. doi: 10.1038/ng.2424
113. Xie Q, Leng L, Lv J, et al. Saw Palmetto-Based Nutritional Supplement Prostataplex Relieves Symptoms of Benign Prostatic Hyperplasia (BPH) in Patients with Mild to Moderate BPH. The Open J Urology. 2012; 2: 104-108.
114. Jin P, Sheng J, Wu Z, et al. Combined Fecal Transferrin Test and Immuno Fecal Occult Blood Test for Detecting Colorectal Cancer and Advanced Adenoma in Asymptomatic and Symptomatic Populations. J. Cancer Science and Therapy. 2012; 4(8): 243-248.
115. Love SM, Zhang W, Gordon EJ, et al. A feasibility study of the intraductal administration of chemotherapy. Cancer Prev Res (Phila). 2013; 6(1): 51-58.
116. He YQ, Sheng JQ, Ling XL, et al. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-β in colorectal cells. Exp Mol Med. 2012; 44(12): 723-732.
117. Moatamed NA, Rao JY, Alexanian S, et al. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens. Cancer Cytopathol. 2013.
118. Cai Y, Shi R, Song H, Shang M, et al. Effects of Lung Support Formula on respiratory symptoms among older adults: results of a three-month follow-up study in Shanghai, China. Nutr J. 2013; 12: 57.
119. Jeon C, Chang SC, Mu L, et al. Genetic Variants of Peroxisome Proliferator-Activated Receptor δ Are Associated with Gastric Cancer. Dig Dis Sci. 2013. doi: 10.1007/s10620-013-2770-2
120. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013; 13(4): 280-286.
121. Freedland SJ, Carducci MA, Kroeger N, et al. A double-blind, randomized, neoadjuvant study of the tissue effects of pomx pills in men with prostate cancer prior to radical prostatectomy. Cancer Prev Res (Phila). 2013.
122. Che J, Mach AJ, Go DE, et al. Microfluidic purification and concentration of malignant pleural effusions for improved molecular and cytomorphological diagnostics. PLoS One. 2013; 8(10): e78194.
123. Jin P, Wu ZT, Li SR, et al. Colorectal cancer screening with fecal occult blood test: A 22-year cohort study. Oncol Lett. 2013; 6(2): 576-582. doi: 10.3892/ol.2013.1402
124. Tarleton HP, Chang SC, Park SL, et al. Genetic variation at 8q24, family history of cancer, and upper gastrointestinal cancers in a Chinese population. Fam Cancer. 2013. 125. Yang T, Chang PY, Park SL, et al. Tobacco smoking, NBS1 polymorphisms, and survival in lung and upper aerodigestive tract cancers with semi-Bayes adjustment for hazard ratio variation. Cancer Causes Control. 2013.
126. Moatamed NA, Vergara-Lluri ME, Lu D, Apple SK, Kerkoutian S, Rao JY. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions. Hum Pathol. 2013; 44(11): 2509-2517.
127. Tse H, Gossett D, Sohsman M, et al. Improved classification of malignant pleural effusions by single-cell mechanophenotyping. Science Transl. Med. 2013; 5(212): 212ra163.
128. Zhao C, Li Z, Nayar R, et al. Prior High-Risk Human Papillomavirus Testing and Papanicolaou Test Results of 70 Invasive Cervical Carcinomas Diagnosed in 2012: Results of a Retrospective Multicenter Study. Arch Pathol Lab Med. 2014.
129. Liu B, Tahk S, Yee KM, et al. PIAS1 Regulates Breast Tumorigenesis through Selective Epigenetic Gene Silencing. PLoS One. 2014; 9(2): e89464.
130. Liu H, Lu S, Gu L, et al. Modulation of BAG-1 Expression Alters the Sensitivity of Breast Cancer Cells to Tamoxifen. Cell Physiol Biochem. 2014; 33(2): 365-374.
131. Lu S, Qin X, Yuan S, et al. Effect of Tianshengyuan-1 (TSY-1) on telomerase activity and hematopoietic recovery – in vitro, ex vivo, and in vivo studies. Int J Clin Exp Med. 2014; 7(3):597-606.
132. Hu Y, Zhao Q, Rao J, Deng H, Yuan H, Xu B. Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009. BMC Public Health. 2014; 14(1): 356. doi: 10.1186/1471-2458-14-356
133. Sharma S, Santiskulvong C, Rao J, Gimzewski JK, Dorigo O. The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Integr Biol (Camb). 2014.
134. Zhao C, Li Z, Nayar R, et al. Prior High-Risk Human Papillomavirus Testing and Papanicolaou Test Results of 70 Invasive Cervical Carcinomas Diagnosed in 2012: Results of a Retrospective Multicenter Study. Arch Pathol Lab Med. 2014.
135. Yang Y, Burke RV, Jeon CY, et al. Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer. 2014.
136. Wang X, Li Y, Tian H, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014; 14: 578. doi: 10.1186/1471-2407-14-578
137. Vergara-Lluri ME, Hu E, Rao J, Levin M, Apple SK, Moatamed NA. Comparative evaluation of ProEx C and ImmunoCyt/uCyt assays in atypical urine cytology. Arch Pathol Lab Med. 2014; 138(9): 1215-1222.
138. Seideman C, Canter D, Kim P, et al. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol. 2014.
139. Wickramaratne D, Wilkinson P, Rao J, Ragavendra N, Sharma S, Gimzewski JK. Fine Needle Elastography (FNE) device for biomechanically determining local variations of tissue mechanical properties. J Biomech. 2014.
140. Kandukuri S, Rao J. FIGO 2013 staging system for ovarian cancer: What is new in comparison to the 1988 staging system? Current Opinion in Obstetrics and Gynecology. 2015; 27(1): 48-52. doi: 10.1097/GCO.0000000000000135
141. Wang F, Lou JF, Cao Y, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med. 2015; 47: e162. doi: 10.1038/emm.2015.17

BOOK CHAPTERS

1. Hurst RE, Rao J. Basic Concept of Molecular Biology. In: Schulte P, ed. Molecular Epidemiology. Academic Press, 1993.
2. Bonner RB, Hurst RE, Rao J, Hemstreet GP. Instrumentation, accuracy and quality control in development of quantitative fluorescence image analysis. In: Hanausek M, ed. Tumor Marker Protocols. Series: Methods in Molecular Biology, Humana Press, Totowa, NJ, 1998: 14.
3. Rao J, Hurst RE, Hemstreet GP. Molecular Pathology of Early Bladder Cancer. In: Srivastava S, et al, ed. Molecular Pathology of Early Cancer. IOS press, Chapter 5, Amsterdam, Netherlands, 1999.
4. Hemstreet GP, Bonner RB, Hurst RE, Rao J. Cytology of Bladder Cancer. In: Vogelzang et al, eds. Comprehensive Textbook of Genitourinary Oncology. Lippincott Williams & Wilkins. 2nd ed, Chapter 20, Philadelphia, PA, 2000.
5. Tsai H, Hemstreet GP, Seligson D, Zhang ZF, Rao J. Tissue Microarray and Quantitative Fluorescence Image Analysis in Tumor Biomarker Analysis. Immunohistochemistry and in-situ Hybridization of Human Carcinomas. Elsevier Science, 2006.
6. Bao R, Rao J. Cervical and Vaginal Cytology. Gynecological Diagnostic Pathology (2nd edition). In: Cheng L, ed Chinese Military Medical Publishing Inc, Chapter 12, 2010.
7. Ye D, Gu P, Zhao H, Chow M, Guo X, Rao J. Evidence-based Anticancer Herbal Medicine for Bladder Cancer. Evidence-based Anticancer Complementary and Alternative Medicine: Herbal Medicine for Various Cancers. Chapter 10, Springer, 2011.